Frequently Asked Questions About Ipamorelin

Ipamorelin is a pentapeptide that selectively binds the ghrelin/GHS-R1a receptor on pituitary somatotrophs, prompting pulsatile growth hormone release. At doses producing robust GH release in rat and swine models, it did not significantly elevate ACTH, cortisol, or prolactin — a selectivity profile not shared by earlier GH-releasing peptides. ^[1]

Ipamorelin (NNC 26-0161) is a synthetic pentapeptide with sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. It acts as a selective agonist of GHS-R1a, triggering pulsatile GH release from somatotrophs through Gq/11 calcium mobilization. First described by Raun et al. (1998), it was characterized as the first GHS with selectivity comparable to GHRH. ^[1]

The 1998 Raun et al. paper in European Journal of Endocrinology characterized ipamorelin as the first GHS that did not significantly elevate ACTH, cortisol, or prolactin — distinguishing it from GHRP-6 and GHRP-2. At doses exceeding 200-fold the GH-releasing ED50, cortisol and prolactin remained unaffected. ^[1]

Ipamorelin produces dose-dependent, pulsatile GH release in rat and swine models and in primary rat pituitary cell cultures. In vivo doses of 2.3–80 nmol/kg IV produced robust, dose-dependent GH release; in vitro EC50 was approximately 1.3 nmol/L. Peak GH response occurs within 15–30 minutes of subcutaneous administration in published animal studies. ^[1]

In preclinical models, ipamorelin at research doses showed a favorable tolerability profile. Cortisol and prolactin were not significantly elevated. ^[1][2] Injection-site reactions and transient flushing have been noted in early-phase human studies. The Phase 2 human trial (NCT00672074) reported no serious adverse reactions attributed to ipamorelin. ^[11] The GH-independent adiposity finding (increased fat pad weight and leptin in mice) is a potential metabolic consideration. ^[10]

Raun et al. (1998) showed ipamorelin did not significantly elevate ACTH, cortisol, or prolactin in rat and swine models at doses producing robust GH release. This remained true at doses exceeding 200-fold the GH-releasing ED50 — the defining selectivity finding distinguishing ipamorelin from GHRP-2 and GHRP-6. ^[1][2]

GHRP-6 strongly stimulates ghrelin-mediated appetite pathways. Ipamorelin's receptor selectivity profile results in substantially less orexigenic activity in preclinical models; human appetite data is limited. The Lall et al. (2001) study did show increased food intake and leptin in normal mice treated with ipamorelin, though less pronounced than GHRP-6 orexigenic effects. ^[10]

Direct belly-fat reduction by ipamorelin alone has not been demonstrated in controlled human trials. In rodent models, GH secretagogues influence lipolysis pathways, but the Lall et al. (2001) study showed GH-independent increases in fat pad weight and leptin in both GH-deficient and GH-intact mice treated with ipamorelin — complicating the simple lipolysis narrative. ^[10]

Published research does not document a direct testosterone-stimulating effect from ipamorelin. GH secretagogues act on the somatotropic axis, not the hypothalamic-pituitary-gonadal axis; testosterone was not a measured endpoint in any published ipamorelin study. No HPG-axis effect has been reported. ^[1]

GH elevation is associated with some fluid retention in the pharmacologic-dose literature; whether ipamorelin-induced pulsatile GH pulses produce clinically significant water retention has not been examined in controlled studies. No controlled ipamorelin water-retention data exists; theoretical extrapolation from exogenous GH data involves uncertainty given ipamorelin's physiologic-magnitude pulsatile GH release versus pharmacologic continuous GH elevation.

Ipamorelin preserves pulsatility and requires intact pituitary function; exogenous GH produces continuous elevation that bypasses somatostatin feedback. Researchers have theorized this mechanistic difference may carry different safety implications. ^[17] Direct long-term controlled human comparison data between secretagogue-derived pulsatile GH and pharmacologic exogenous GH is absent from the published literature.

Ipamorelin has a short plasma half-life in rat models, with biexponential plasma concentration decline after IV bolus (Johansen et al. 1998, PMID 9879640). ^[9] The brief duration supports the multiple-injections-per-day approach used in most published animal protocols. Human pharmacokinetic data for subcutaneous administration is not available from published studies.

In animal models, acute GH elevation is observed within 15–30 minutes of injection; the pulse resolves within hours. Downstream IGF-1 changes appear after multi-week dosing: the Johansen 1999 bone growth study ran 15 days; the Andersen 2001 bone model ran 3 months. ^[3][4] Controlled human timeline data for GH, IGF-1, or anabolic endpoints does not exist in the published literature.

Pre-sleep timing is theorized to align with physiologic GH surge during slow-wave sleep. Fasting-state administration is documented in some protocols to minimize somatostatin tone. No controlled head-to-head timing comparison has been published for ipamorelin specifically; both rationales derive from general GH physiology rather than ipamorelin-specific trial data.

Published animal studies use per-injection doses scaled to body weight, given multiple times daily. The Andersen 2001 protocol used three injections/day; Malmlöf 1999 used four IV doses/day; Venkova 2009 used four IV doses at 3-hour intervals. ^[4][6][8] Per-dose vs per-day framing is protocol-dependent and not standardized across the published literature.

Jiménez-Reina et al. (2002) showed 21-day chronic ipamorelin treatment did not produce tachyphylaxis in rats — somatotrophs from treated animals showed enhanced in vitro GH response to subsequent ipamorelin challenge. ^[7] Long-term desensitization data beyond 21 days is not published. Controlled human data on optimal cycle length is absent from the peer-reviewed literature.

IGF-1 is the primary downstream marker used in published GH secretagogue studies. ACTH and cortisol panels are included in selectivity safety assessments. Glucose and insulin sensitivity have been measured in some GH-axis intervention studies. No dedicated ipamorelin-specific biomarker monitoring protocol has been published in peer-reviewed literature. ^[1][8]

Tesamorelin is FDA-approved for HIV-associated lipodystrophy at 2 mg SC daily; sermorelin is a GHRH analog; ipamorelin is a GHRP acting at GHS-R1a. They differ in receptor target, pulsatility profile, and studied indications. A like-for-like efficacy comparison does not exist in the published record; tesamorelin is the only one of the three with an FDA-reviewed clinical indication. ^[1][14]

At equimolar doses, GHRP-6 raised cortisol and ACTH significantly; ipamorelin produced equivalent GH release without these hormone elevations. GHRP-6 activates appetite-stimulating ghrelin pathways more broadly; ipamorelin's selectivity at GHS-R1a produces cleaner GH pulses in preclinical models. ^[1][2]

Sermorelin and CJC-1295 are GHRH analogs acting at GHRHR; ipamorelin is a GHRP acting at GHS-R1a. They represent distinct receptor families with complementary mechanisms. Combining GHRH-pathway and ghrelin-pathway stimulation produces supraadditive GH release in preclinical models versus either agent alone. ^{[1][12][16][18][19]}

CJC-1295 acts at GHRHR via cAMP/PKA; ipamorelin acts at GHS-R1a via Gq/11/calcium. Both converge on somatotroph GH exocytosis. Co-activating two complementary pathways produces GH release greater than either peptide alone in preclinical models; CJC-1295 provides a prolonged GHRH signal while ipamorelin adds the ghrelin-pathway amplification. ^[16][18][19]

MK-677 (ibutamoren) is an orally active GHS-R1a agonist with a long half-life that produces more sustained GH and IGF-1 elevation than ipamorelin's short-duration pulses. Mechanism targets are similar (GHS-R1a), but pharmacokinetic profiles and side-effect data differ substantially. No controlled comparative trial exists for MK-677 versus CJC-1295/ipamorelin.

Ipamorelin is not FDA approved for any indication. It completed one Phase 2 clinical trial (NCT00672074, n=117) for postoperative ileus that did not meet its primary efficacy endpoint. It is classified as a research chemical. Compounding pharmacy classification has shifted since 2023 and remains in regulatory flux as of early 2026. ^[11]

Venkova et al. (2009) reported ipamorelin accelerated recovery of gastrointestinal contractile function after postoperative ileus in animal models. ^[6] In the Phase 2 human trial (NCT00672074, n=117), median time to first tolerated meal was 25.3 h (ipamorelin) vs 32.6 h (placebo); the difference did not reach statistical significance (p=0.15). ^[11]

Multiple animal studies including Venkova et al. (2009) document ipamorelin's prokinetic effects on GI contractility via GHS-R1a activation in the enteric nervous system. ^[6][13] The GI motility research — and the Phase 2 human trial derived from it — represents the most clinically advanced chapter of the ipamorelin literature and the only work that includes human patient data.

Andersen et al. (2001; PMID 11735244) showed ipamorelin prevented glucocorticoid-induced reductions in bone formation markers in adult rats, producing a four-fold increase in periosteal bone formation rate versus glucocorticoid alone. Maximum tetanic tension was also significantly improved in the combination group. ^[4]

Preclinical models show sustained ipamorelin dosing increases circulating IGF-1 as a downstream consequence of elevated GH pulses. ^[8][22] In the Malmlöf et al. (1999) model, ipamorelin prevented glucocorticoid-associated IGF-1 decline. Individual responsiveness varies; no controlled human IGF-1 response data for ipamorelin exists in published trials.

GH is naturally released during slow-wave sleep. Pre-sleep administration of GH secretagogues has been studied for alignment with physiologic GH rhythms in general GH-physiology research. Sleep quality as a primary endpoint has not been assessed in any controlled ipamorelin trial. No ipamorelin-specific sleep data exists in the published literature.